Latest Breaking News On - Cullinan therapeutics - Page 4 : comparemela.com

A recent academic case study, published on April 22, examined using Amgen Inc’s AMGN Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with…

Amgen incCullinan therapeutics incCullinan therapeuticsCullinan oncologyReaking news